Deal roundup: Zymeworks/Celgene, Curis/Aurigene, MedImmune/NCI

Zymeworks will earn up to $164m in clinical, regulatory and commercial milestone fees plus royalties for each bi-specific antibody developed under a new collaboration with Celgene.

Zymeworks will earn up to $164m in clinical, regulatory and commercial milestone fees plus royalties for each bi-specific antibody developed under a new collaboration with Celgene.

Vancouver, British Columbia-based Zymeworks also received an undisclosed upfront payment and an equity investment from Celgene to use its Azymetric...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category